Geographic Atrophy and Intravitreal Ranibizumab Injections
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Given the aging population who will be affected by wet AMD and lack of effective GA
treatment, it is crucial to assess the safety profile of repeated ranibizumab injections in
AMD patients with GA, particularly the possible risk of GA development and enlargement. This
potential adverse effect has significant implication in the discussions with patients
regarding the risks and benefits of AMD treatment and injection frequency. While monthly
injections provide slight improvement of visual acuity at 2 years (Martin et al., 2012), the
risk of GA enlargement may offset this benefit in visual acuity.
Previous studies assessed the association between intravitreal ranibizumab injections and de
novo GA development in injection-naïve eyes (Martin et al, 2012, Querques et al., 2012.,
Grunwald et al., 2014), rather than GA enlargement in patients with preexisting GA. To the
best of the investigators knowledge, there has been no prospective study assessing the
association between intravitreal ranibizumab injections and rate of GA progression in
patients with pre-existing GA. There is also no prospective study comparing the morphological
features of GA between patients who are receiving intravitreal injections and those who are
not, nor the concordance of GA enlargement rate between the 2 eyes among patients receiving
and not receiving treatment.